Connor, Clark & Lunn Investment Management Ltd. Durect Corp Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022
BUY
$0.43 - $5.9 $1,326 - $18,201
3,085 Added 0.82%
377,338 $218,000
Q2 2022

Aug 05, 2022
BUY
$0.38 - $0.64 $112,298 - $189,134
295,523 Added 375.36%
374,253 $179,000
Q1 2022

May 12, 2022
BUY
$0.55 - $0.98 $43,301 - $77,155
78,730 New
78,730 $53,000

Others Institutions Holding DRRX

# of Institutions
3
Shares Held
593K
Call Options Held
0
Put Options Held
0
View Full List

About DURECT CORP

DRRX Quotes by TradingView
  • Ticker DRRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 227,794,000
  • Market Cap $171M
  • Description
  • DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...
More about DRRX
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email